To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Sweden (ECOS SWE)

This study is currently recruiting participants.
Verified December 2013 by Merck KGaA
Sponsor:
Collaborator:
Merck A.B., Sweden
Information provided by (Responsible Party):
Merck KGaA
ClinicalTrials.gov Identifier:
NCT01307059
First received: March 1, 2011
Last updated: December 12, 2013
Last verified: December 2013
  Purpose

This is a Swedish, Multicentre, Observational Registry to study Adherence and Long Term Outcomes of Therapy in paediatric subjects using Easypod™ electromechanical device for growth hormone treatment to assess the level of adherence of subject receiving SAIZEN® via Easypod™.


Condition Intervention
Growth Disorders
Device: easypod™

Study Type: Observational
Study Design: Observational Model: Cohort
Official Title: Easypod Connect: A Swedish, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment

Resource links provided by NLM:


Further study details as provided by Merck KGaA:

Primary Outcome Measures:
  • Mean percent of daily recorded adherence [ Time Frame: At least 6 months and up to 5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Correlation of adherence and growth outcome (change in height velocity (HV), height velocity-standard deviation score (HV-SDS), height, height-standard deviation score(height SDS) after each year of SAIZEN® treatment with Easypod™ [ Time Frame: At least 6 months and up to 5 years ] [ Designated as safety issue: No ]
  • Subject adherence profile based on age, gender, indication, self-injection or not, time on treatment [ Time Frame: At least 6 months and up to 5 years ] [ Designated as safety issue: Yes ]
  • Correlation of adherence with current IGF-1 status (i.e. above, below or within normal ranges) [ Time Frame: At least 6 months and up to 5 years ] [ Designated as safety issue: Yes ]
  • Correlation of adherence and HbA1C [ Time Frame: At least 6 months and up to 5 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 119
Study Start Date: June 2011
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: easypod™
    Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
    Other Name: Somatotropin
Detailed Description:

Subjects will be enrolled in a multicenter longitudinal observational registry. Parents/subjects will provide their Informed Consent/assent to upload their data for population-based analyses and optionally to adhere to a patient adherence support program designed to improve their adherence and, ultimately, clinical outcomes. Adherence data will be primarily derived from the Easypod™ device combined with physician data entry of outcome measures. Data will be collected retrospectively and prospectively. This will allow the establishment of adherence profiles and explore the hypothesis that patient adherence support programs improve adherence and subsequent clinical outcomes. Collected data will be also analyzed in a multinational pooled analysis of comparable national studies.

Primary Objective:

• To assess the level of adherence of subjects receiving SAIZEN® via Easypod™

Secondary Objectives:

  • To describe the impact of adherence on clinical outcomes for subject receiving SAIZEN® via Easypod™
  • To identify adherence subject profiling based on age, gender, self injection or not, time on treatment, medical history at time of enrollment
  • To assess the impact of adherence on Insulin-like Growth Factor 1 (IGF1) (i.e. above, below or within normal ranges)

Other Objectives:

• To assess the impact of adherence on average blood glucose (HbA1C)

  Eligibility

Ages Eligible for Study:   2 Years to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Paediatric subjects (aged 2-18) who are taking SAIZEN® for registered indications using the Easypod™ electromechanical device.

Criteria

Inclusion Criteria:

  • Administered growth hormone via the EasypodTM electromechanical device according to Summary of Product Characteristics (SmPC)
  • Over the age of > 2 years old
  • Under < 18 years of age, or over 18 years of age without fusion of growth plates
  • Parent's or guardian's written informed consent, given before entering data into the registry , with the understanding that the subject or parent/guardian may withdraw consent at any time without prejudice to future medical care. If the child is old enough to read and write, a separate assent form will be given as defined in the appropriate jurisdiction of each country.

Exclusion Criteria:

  • Subjects taking growth hormone in whom growth plates have fused (i.e. for taking growth hormone for it's metabolic effects)
  • Contra-indications to SAIZEN® as defined in the SmPC
  • Use of an investigational drug or participation in an interventional clinical study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01307059

Contacts
Contact: Merck KGaA Communication Center +49-6151-72-5200 service@merckgroup.com

Locations
Sweden
Merck Serono Research Site Recruiting
Göteborg, Sweden
Merck Serono Research Site Recruiting
Solna, Sweden
Merck Serono Research Site Recruiting
Uppsala, Sweden
Sponsors and Collaborators
Merck KGaA
Merck A.B., Sweden
Investigators
Study Director: Medical Responsible Merck A.B., Sweden
  More Information

No publications provided

Responsible Party: Merck KGaA
ClinicalTrials.gov Identifier: NCT01307059     History of Changes
Other Study ID Numbers: EMR 200104-524
Study First Received: March 1, 2011
Last Updated: December 12, 2013
Health Authority: Sweden: Regional Ethical Review Board

Keywords provided by Merck KGaA:
Growth disorders
Saizen
Easypod
Growth hormone
Pediatric subject

Additional relevant MeSH terms:
Growth Disorders
Pathologic Processes

ClinicalTrials.gov processed this record on April 17, 2014